Biocon Biologics Partners with Adagio Therapeutics to Advance Covid-19 Antibody Drug
The company ‘Biocon Biologics’ announced, Adagio Therapeutics based in the United States has granted an exclusive license to Biocon Biologics for the purpose of manufacturing and commercializing an antibody treatment, which is going to be based on ADG20 for the Indian Market and several other selected emerging markets. The ADG20 is a novel monoclonal antibody, […]
Continue Reading